Search Results

IASO Biotechnology (“IASO Bio”) today announces that the investigational new drug (IND) application for RD118, an independently developed, fully human GPRC5D-targeting chimeric antigen receptor T-cell (CAR-T) therapy, has been approved by the National Medical Products Administration (NMPA) for treatment of relapsed/refractory multiple myeloma (RRMM).

IASO biotechnology presented the clinical data and single-cell analysis of the fully human anti-BCMA CAR T cell therapy for the treatment of central nervous system autoimmunity in an oral presentation at the 2024 European Academy of Neurology Annual Meeting.

Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into a Settlement and License Agreement (Agreement) with Cipla Ltd. and Cipla USA, Inc. (collectively Cipla).

IASO biotechnology presented clinical data on the use of Equecabtagene Autoleucel, the world’s first approved fully human CAR-T product, for the treatment of transplant-ineligible patients with high-risk newly diagnosed multiple myeloma in an oral presentation at the 2024 European Hematology Association Annual Congress.

IASO Biotherapeutics announced a new set of collaborations with Umoja Biopharma, Inc., a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR-T cell therapies in oncology and autoimmunity, for the development and commercialization of novel ex vivo and in vivo cell and gene therapies.

IASO Biotechnology is pleased to announce that the Investigational New Drug application for its BCMA CAR-T has been approved by the U.S. Food and Drug Administration for use in U.S. clinical trials for generalised myasthenia gravis.

IASO Bio announced that China National Medical Products Administration has approved the Investigational New Drug application for Equecabtagene Autoleucel, a self-developed fully-human anti-B cell maturation antigen chimeric antigen receptor autologous T-cell injection, for an expanded indication in treating relapsed and/or refractory multiple myeloma patients who have undergone 1-2 lines of prior therapies and are refractory to lenalidomide.